Top 10 healthcare ETFs to watch in 2026

By Stake Desk10 min read
doctor-using-microscope-in-lab.jpg

You know these companies by the pill bottles in your cabinet and the scanner your GP ordered. Some funds hold the whole sector while others narrow to biotech or pharma.

Healthcare ETFs hold stocks across the sector – pharmaceuticals, biotech, medical devices and health insurers – wrapped into a single exchange-traded fund. The ten funds here are all U.S.-listed, but their structures vary. ARK Genomic Revolution ETF ($ARKG) is actively managed rather than index-tracking, and iShares Global Healthcare ETF ($IXJ) includes companies from outside the U.S. Management fees across this list range from 0.08% to 0.75%.

How we built this list: We selected these funds based on their investment category and relevance to the theme, then ordered them by assets under management. Prices are updated daily, and the list and supporting content are reviewed roughly every quarter. All data is sourced from Stake. This list isn't a recommendation and isn't ordered by suitability.

ETF Name

Ticker

Share Price

AUM

Expense Ratio

In Watchlists

State Street Health Care Select Sector SPDR ETF

XLV

$185.24

$50.32B

0.08%

1537

Vanguard Health Care ETF

VHT

$341.07

$20.80B

0.09%

1401

iShares Biotechnology ETF

IBB

$206.97

$10.83B

0.44%

943

State Street SPDR S&P Biotech ETF

XBI

$145.28

$9.82B

0.35%

1141

iShares US Healthcare ETF

IYH

$77.38

$4.88B

0.37%

175

iShares Global Healthcare ETF

IXJ

$112.74

$4.71B

0.38%

409

Fidelity MSCI Health Care Index ETF

FHLC

$88.19

$4.11B

0.08%

130

ARK Genomic Revolution ETF

ARKG

$40.50

$1.85B

0.75%

7869

VanEck Pharmaceutical ETF

PPH

$120.09

$1.09B

0.35%

179

Invesco S&P 500 Eql Wght Health Care ETF

RSPH

$40.31

$1.06B

0.40%

75

Past performance is not a reliable indicator of future performance.

Source: Stake market data. Figures in US$. Data updated as of 17 November 2026.

✅ Learn more: Top 6 ARK ETFs to watch in 2026→

Looking to invest in Healthcare ETFs?

Sign up in minutes and get razor-sharp access to Wall St, where you can explore Healthcare ETFs and more.

doctor-using-microscope-in-lab.jpg

1. State Street Health Care Select Sector SPDR ETF ($XLV)

XLV 1-year price chart: up 22.1%, from US$151.70 to US$185.24. Range US$142.84 to US$189.66.

Price: US$185.24 · Daily: -1.4% · AUM: US$50.32B · MER: 0.08%

State Street Health Care Select Sector SPDR ETF ($XLV) is designed to track the Health Care Select Sector Index, aiming to match its price and yield performance before expenses. The fund keeps at least 95% of its assets in the index's securities under normal market conditions. That close alignment ties $XLV tightly to its benchmark rather than allowing active drift.

The index covers healthcare companies across pharmaceuticals, biotechnology, medical devices and managed care. State Street Health Care Select Sector SPDR ETF ($XLV) is passively managed, so the portfolio shifts only when the index itself changes. No portfolio manager steps in to override the holdings between reconstitutions.

2. Vanguard Health Care ETF ($VHT)

VHT 1-year price chart: up 20.8%, from US$282.25 to US$341.07. Range US$265.36 to US$351.23.

Price: US$341.07 · Daily: -1.3% · AUM: US$20.80B · MER: 0.09%

The MSCI U.S. Investable Market Health Care Index covers U.S. healthcare companies across large-, mid- and small-cap segments, and Vanguard Health Care ETF ($VHT) aims to track that benchmark. The index's small- and mid-cap inclusion extends $VHT's reach well beyond the sector's largest companies.

Because the fund is passively managed, its holdings reflect the index rather than any active stock selection. Companies can enter or leave the benchmark when MSCI rebalances the index, and the fund adjusts to match. That means the portfolio's composition reflects the current make-up of U.S. healthcare as MSCI classifies it.

3. iShares Biotechnology ETF ($IBB)

IBB 1-year price chart: up 25.2%, from US$165.26 to US$206.97. Range US$160.41 to US$221.13.

Price: US$206.97 · Daily: -0.5% · AUM: US$10.83B · MER: 0.44%

iShares Biotechnology ETF ($IBB) aims to track the ICE Biotechnology Index, which covers U.S.-listed companies classified within the biotechnology sub-industry. The fund is designed to hold at least 90% of its assets in securities from that index.

Biotechnology companies focus on developing drugs, therapies and diagnostics through biological processes – a narrower slice of healthcare than a broad sector fund. Because the index is confined to a single sub-industry, the portfolio is more concentrated than a fund covering healthcare more broadly.

4. State Street SPDR S&P Biotech ETF ($XBI)

XBI 1-year price chart: up 26.5%, from US$114.83 to US$145.28. Range US$113.83 to US$169.55.

Price: US$145.28 · Daily: -0.4% · AUM: US$9.82B · MER: 0.35%

State Street SPDR S&P Biotech ETF ($XBI) is a passively managed fund that aims to track the S&P Biotechnology Select Industry Index. That index is drawn from the biotechnology segment of a U.S. total market composite index, so the fund's coverage is concentrated within that one corner of healthcare.

Because $XBI follows a rules-based index rather than an active manager's picks, its holdings shift when the index rebalances rather than on a fund manager's judgement. Biotech is a volatile corner of the market – companies here are often pre-revenue and driven by clinical trial outcomes – so the index construction matters a great deal to what the fund actually holds at any point.

5. iShares US Healthcare ETF ($IYH)

IYH 1-year price chart: up 21.3%, from US$63.78 to US$77.38. Range US$59.98 to US$79.85.

Price: US$77.38 · Daily: -1.3% · AUM: US$4.88B · MER: 0.37%

iShares US Healthcare ETF ($IYH) aims to track the Russell 1000 Health Care RIC 22.5/45 Capped Index, which measures the performance of the healthcare sector within the U.S. equity market. The fund is designed to invest in the component securities of that index, keeping its portfolio anchored to large-cap U.S. healthcare names.

The 'capped' structure in the index name refers to concentration limits applied at the security level – designed to prevent any single holding from dominating the fund's exposure. That construction shapes how the portfolio is weighted across pharmaceuticals, medical devices, biotech and other healthcare industries within U.S. large-cap stocks.

Join 1M+ on Stake

Effortless investing in U.S. shares & ETFs

6. iShares Global Healthcare ETF ($IXJ)

IXJ 1-year price chart: up 18.1%, from US$95.48 to US$112.74. Range US$90.75 to US$115.53.

Price: US$112.74 · Daily: -1.3% · AUM: US$4.71B · MER: 0.38%

The iShares Global Healthcare ETF ($IXJ) is designed to track the S&P Global Healthcare Sector Index – a subset of the S&P Global 1200 Index. Standard & Poor's builds that index from companies it considers both part of the healthcare sector and important to global markets. That construction means $IXJ holds healthcare names beyond U.S. borders, reflecting the international scope of the underlying index.

7. Fidelity MSCI Health Care Index ETF ($FHLC)

FHLC 1-year price chart: up 21.2%, from US$72.75 to US$88.19. Range US$68.53 to US$90.77.

Price: US$88.19 · Daily: -1.3% · AUM: US$4.11B · MER: 0.08%

Fidelity MSCI Health Care Index ETF ($FHLC) is designed to track the MSCI USA IMI Health Care Index, which covers the health care sector across the U.S. equity market. The fund aims to invest at least 80% of its assets in securities drawn from that index.

The index takes a broad approach to U.S. health care, pulling in companies from across pharmaceuticals, biotech, medical devices and health insurers rather than narrowing to one corner of the sector. That construction means $FHLC's performance is tied closely to the direction of U.S. health care stocks as a whole.

8. ARK Genomic Revolution ETF ($ARKG)

ARKG 1-year price chart: up 50.7%, from US$26.87 to US$40.50. Range US$24.82 to US$56.77.

Price: US$40.50 · Daily: -0.3% · AUM: US$1.85B · MER: 0.75%

ARK Genomic Revolution ETF ($ARKG) is actively managed, meaning a portfolio team selects holdings rather than tracking a fixed index. The fund aims to achieve long-term capital growth by investing in companies the manager believes will benefit from advances in genomics.

Its mandate is broad – $ARKG can hold equities across healthcare, information technology, materials, energy and consumer discretionary. That flexibility means the portfolio can reach into sectors beyond traditional healthcare, wherever the manager identifies genomics-related opportunity.

9. VanEck Pharmaceutical ETF ($PPH)

PPH 1-year price chart: up 21.2%, from US$99.10 to US$120.09. Range US$97.57 to US$122.65.

Price: US$120.09 · Daily: -1.2% · AUM: US$1.09B · MER: 0.35%

VanEck Pharmaceutical ETF ($PPH) is designed to replicate, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index. That index covers U.S.-listed common stocks of companies in the pharmaceutical industry. With 25 names in the benchmark, the construction is deliberately concentrated – a tight focus on pharma rather than a broad sweep across healthcare.

The fund's mandate requires at least 80% of its assets to stay in index securities, keeping the portfolio anchored to pharmaceutical companies specifically. That separates $PPH from wider healthcare funds that mix in medical devices, biotechs or health insurers alongside drug makers.

10. Invesco S&P 500 Eql Wght Health Care ETF ($RSPH)

RSPH 1-year price chart: up 30.7%, from US$30.84 to US$40.31. Range US$29.59 to US$41.56.

Price: US$40.31 · Daily: -1.3% · AUM: US$1.06B · MER: 0.40%

Invesco S&P 500 Eql Wght Health Care ETF ($RSPH) is designed to track the S&P 500 Equal Weight Health Care Index, which covers healthcare companies drawn from the S&P 500. The equal-weight approach is the defining feature: every constituent is weighted roughly the same, rather than giving larger companies a proportionally bigger share of the fund.

That construction means smaller healthcare names get as much influence on the fund's performance as the sector's bigger players. A standard market-cap-weighted healthcare fund tends to concentrate heavily in a handful of large pharmaceutical and insurance companies; $RSPH is intended to spread that exposure more evenly across the index. The fund aims to hold at least 90% of its assets in the securities that make up the underlying index, in proportion to their index weightings.

The fund holds U.S.-listed healthcare stocks only, covering companies across pharmaceuticals, biotech, medical devices and health insurers that are included in the S&P 500.

Common questions

How do I invest in healthcare ETFs in New Zealand?

Every fund in this list trades on a U.S. exchange, so you'd access them through a share trading platform that connects to U.S. markets. You search by ticker, place an order during U.S. market hours, and the fund holds a portfolio of healthcare stocks on your behalf.

What are the key risks of healthcare ETFs?

Some of the key risks include sector concentration, company-specific outcomes within certain sub-sectors, and currency exposure. A fund focused solely on healthcare has no other industry to cushion a downturn specific to the sector. Biotech-focused funds carry an additional layer of risk because many companies in that sub-industry depend on clinical trial results or a regulator's sign-off before they can commercialise a product. Currency movements between the New Zealand dollar and the U.S. dollar affect what purchases cost and what proceeds are worth, since all ten funds are priced in USD. For actively managed funds, there's also the risk that the manager's selections diverge from broader market returns.

How do the funds in this list differ by focus?

The funds here cover several distinct corners of healthcare. Broad sector funds track the full sweep – pharmaceuticals, medical devices, biotech and health insurers – while biotech-focused funds narrow to companies developing biological therapies and drugs, making them more sensitive to clinical trial outcomes. $PPH concentrates further still, holding only pharmaceutical companies, and $IXJ widens the geography to include healthcare names outside the U.S. $ARKG takes a structurally different approach as the only actively managed fund in this list, with a portfolio team selecting companies they believe are tied to genomics advances rather than tracking a fixed index.

Disclaimer

Past performance is not a reliable indicator of future performance. When you invest, your capital is at risk. You should consider your own investment objectives, financial situation, and particular needs before making an investment decision. The value of your investments can go down as well as up and you may receive back less than your original investment. As always, do your own research and consider seeking appropriate financial advice before investing.

This is not personal financial advice nor a recommendation to invest in the securities listed. Any advice provided by Stake is of general nature only and does not take into account your specific circumstances. Trading and volume data from the Stake investing platform is for reference purposes only, the investment choices of others may not be appropriate for your needs and is not a reliable indicator of performance.

Please refer to hellostake.com/pricing for the fees that apply. When you trade securities priced in another currency, currency conversion fees may apply and movements in the exchange rate may affect your returns.


Portrait photo of Stake Desk, The freshest market insights at Stake.

Stake Desk

The freshest market insights

This article combines AI and human review from our analysts to bring you accurate, informative investing content at speed. For questions or suggestions, contact stakedesk@stake.com.au.


Subscribe

By subscribing, you agree to our Privacy Policy.

Footer


Bringing Wall St to NZ since 2020

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd is registered as an overseas company in New Zealand (NZBN: 9429047452152), and is registered as a Financial Service Provider under the Financial Service Providers (Registration and Dispute Resolution) Act 2008 (No. FSP774414). We hold a full licence issued by the Financial Markets Authority to provide a financial advice service under the Financial Markets Conduct Act 2013. However, the content on this website has not been prepared to take into account any of your individual objectives, financial situation or needs. To the extent you require further information about the relevant New Zealand legislation that may apply, or require specific advice, please contact your legal and/or financial adviser (as appropriate). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Terms & Conditions, Privacy Policy, Financial Advice Disclosure and Disclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake is a registered trademark under class 36 (New Zealand).

Copyright © 2026 Stake. All rights reserved.